Renal Disease Research Institute

Dallas, Texas 75246

4 studies enrolling now · 18 studies all time

What they study most

ADPKD, Alport Syndrome, Antibody-mediated Rejection, Atherosclerotic Cardiovascular Disease (ASCVD), Autosomal Dominant Polycystic Kidney, Cardiovascular Risk, Chronic Kidney Disease, Chronic Kidney Disease (CKD), Chronic Kidney Diseases, Cytomegalovirus Disease, Diabetes Complications, Diabetes Mellitus

Studies at this site

• Assessing the Impact of Muvalaplin on Major Cardiovascular Events in Adults With Elevated Lipoprotein(a) — Recruiting now
• A Research Study to Look at How Well NNC0487-0111 Works Compared to Placebo in People With Heart Failure and Obesity — Recruiting now
• A Study of Patients With Fabry Disease (US Specific) — Recruiting now
• ZEUS - A Research Study to Look at How Ziltivekimab Works Compared to Placebo in People With Cardiovascular Disease, Chronic Kidney Disease and Inflammation — Completed
• The Effect of Retatrutide Once Weekly on Cardiovascular Outcomes and Kidney Outcomes in Adults Living With Obesity (TRIUMPH-Outcomes) — Running, not enrolling
• Expanding and Promoting Alternative Care and kNowledge in Decision-making Trial — Enrolling by invitation
• The Merit WRAPSODY AV Access Efficacy Study (WAVE) — Completed
• Trial to Evaluate Reduction in Inflammation in Patients With Advanced Chronic Renal Disease Utilizing Antibody Mediated IL-6 Inhibition — Completed
• Clazakizumab for the Treatment of Chronic Active Antibody Mediated Rejection in Kidney Transplant Recipients — Stopped early
• EMPA-KIDNEY (The Study of Heart and Kidney Protection With Empagliflozin) — Completed
• A Study for Kidney Transplant Recipients at High-Risk of Cytomegalovirus Infection — Completed
• A Phase 2/3 Trial of the Efficacy and Safety of Bardoxolone Methyl in Patients With Alport Syndrome - CARDINAL — Completed
• An Extended Access Program for Bardoxolone Methyl in Patients With CKD (EAGLE) — Stopped early
• A Trial of Bardoxolone Methyl in Patients With ADPKD - FALCON — Stopped early
• A Study of TRPC5 Channel Inhibitor in Patients With Diabetic Nephropathy, Focal Segmental Glomerulosclerosis, and Treatment-Resistant Minimal Change Disease — Stopped early
• Establishing the Safety and Efficacy of Reloxaliase in Patients With Enteric Hyperoxaluria — Stopped early
• Pilot Study to Evaluate the Safety and Efficacy of Abatacept in Adults and Children 6 Years and Older With Excessive Loss of Protein in the Urine Due to Either Focal Segmental Glomerulosclerosis (FSGS) or Minimal Change Disease (MCD) — Completed
• Evaluate ALLN-177 in Patients With Enteric Hyperoxaluria — Completed